CClinicalTrials.gg
Not yet recruitingNCT07694089Updated Jul 9, 2026

Steroid Avoidance, Dexamethasone, and RAGE Inhibition for Perioperative Cerebral Edema Management in High-Grade Gliomas

A Phase 2 interventional study of Dexamethasone and Azeliragon in High-grade Gliomas (HGG), sponsored by Akshitkumar MIstry. Not yet recruiting at 2 sites in United States. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-07-09.

Sponsored by Akshitkumar MIstry · Phase 2, Interventional, and Supportive care

Phase
Phase 2
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Study summary

The purpose of this study is to learn whether two alternatives to standard steroid treatment can safely control swelling around a brain tumor after surgery. The study will compare three approaches by placing participants in one of three study groups: standard dexamethasone (a steroid), no routine steroid treatment, and azeliragon, a study drug that may reduce brain swelling through a different pathway. Researchers want to determine whether these alternatives can control swelling while reducing some of the side effects associated with steroid use.

Participants in this study will be randomly assigned to one of three study groups. Participants will undergo their planned brain tumor surgery and receive the treatment assigned to their group. Study procedures are the same as their routine care and include physical and neurological examinations, blood tests, MRI scans, review of medical records, and collection of tumor tissue removed during surgery (optional). Most study visits will occur during routine medical care. Participants will be followed for approximately 24 months after surgery.

Read the detailed description

This study is a randomized Phase II trial because it is designed to evaluate the preliminary efficacy, safety, and feasibility of steroid avoidance and azeliragon as alternatives to dexamethasone for perioperative cerebral edema management in high-grade glioma. The trial uses an intermediate imaging-based efficacy endpoint, enrolls a modest sample size, and is intended to identify promising strategies for subsequent confirmation in a definitive Phase III study.

The trial compares three perioperative strategies-standard dexamethasone, complete steroid avoidance, and RAGE inhibition with azeliragon-to determine their relative safety and effectiveness in controlling cerebral edema following tumor resection. In addition to edema control, the study evaluates clinical, functional, and immunologic outcomes associated with perioperative corticosteroid exposure.

Despite widespread use, dexamethasone lacks prospective evidence defining its optimal perioperative role in glioma patients. This study addresses that gap by rigorously evaluating steroid avoidance and a mechanistically targeted alternative, with the goal of improving patient outcomes while minimizing treatment-related toxicity.

02

Conditions studied

  • High-grade Gliomas (HGG)
03

In context

Lead sponsor

This is the only study on the registry with Akshitkumar MIstry as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

Age ≥18 years at the time of screening

  • Newly diagnosed supratentorial tumor with imaging characteristics consistent with high-grade glioma
  • Candidate for craniotomy with planned resection of more than 50% of the contrast-enhancing tumor
  • Midline shift ≤10 mm on preoperative imaging
  • Limited pre-enrollment corticosteroid exposure (≤10 mg dexamethasone total and no chronic steroid use within 30 days)
  • Karnofsky Performance Status ≥60
  • Adequate organ function to undergo surgery and postoperative care as determined by the investigator
  • Ability to provide informed consent and comply with study procedures
  • Agreement to use effective contraception, when applicable

Exclusion criteria

Exclusion Criteria:

  • Participants meeting any of the following will be excluded:

    • Imaging or clinical features highly suggestive of primary CNS lymphoma or metastatic disease
    • Posterior fossa tumors or lesions associated with high risk of brainstem compression
    • Leptomeningeal or widely disseminated disease
    • Clinical conditions requiring immediate corticosteroid therapy
    • Prior exposure to high-dose corticosteroids (>10 mg dexamethasone) or chronic steroid use within 30 days
    • Active systemic illness that increases surgical risk, including uncontrolled infection, coagulopathy, or severe cardiopulmonary disease
    • Pregnancy or breastfeeding
    • Known immunodeficiency or chronic infection requiring immunosuppressive therapy
    • Use of investigational agents within 30 days or concurrent use of immunosuppressive medications not permitted by protocol
    • Known hypersensitivity to azeliragon
    • Inability to undergo MRI due to contraindications such as incompatible implants or severe claustrophobia
    • Life expectancy less than 3 months as determined by the investigator
    • Participation in another interventional clinical trial prior to initiation of standard adjuvant therapy Vulnerable Populations: This study will not enroll children, pregnant or breastfeeding individuals, or prisoners. Individuals with impaired decision-making capacity may be enrolled only when a legally authorized representative is available to provide consent in accordance with institutional and regulatory requirements.
05

Study design

Phase
Phase 2
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Active comparator
    Dexamethasone Arm

    Standard dexamethasone (steroid) treatment

    Drug: Dexamethasone

  • No intervention
    No-dexamethasone Arm

    No routine dexamethasone treatment

  • Experimental
    Azeliragon Arm

    Azeliragon administered for the treatment of brain cancer and to evaluate its capability to control brain swelling around the time of surgery.

    Drug: Azeliragon

Interventions

  • DrugDexamethasone

    Potent FDA-approved corticosteroid

  • DrugAzeliragon

    orally bioavailable inhibitor of the receptor for advanced glycation endproducts (RAGE)

06

What researchers measure

Primary outcomes

  1. change in peritumoral edema between the preoperative and postoperative period

    The primary outcome is the change in peritumoral edema between the preoperative and postoperative period. Specifically, it is the ratio of postoperative to preoperative peritumoral edema volume, adjusted for extent of enhancing tumor removed. This outcome is derived from MRI-based volumetric assessment and reflects the effectiveness of each perioperative strategy in controlling cerebral edema while accounting for surgical factors

    Time frame: before the start of adjuvant chemo radiation (up to 6 weeks)

07

Study locations

2 sites
  • UofL Health Brown Cancer Center; University of Louisville Hospital
    Louisville, Kentucky 40202, United States
    • UofL Health Brown Cancer Center · Contact · 502-562-4370
  • UofL Health Jewish Hospital
    Louisville, Kentucky 40202, United States
08

References and documents

Individual participant data

Plan to share: Yes — name, address, date of birth, medical history, and other information from your medical records from UofL Health and other institutions involved with this research, as well as from your other healthcare providers (which may include information about HIV status, drug, alcohol or sexually transmitted disease treatment, genetic test results, or mental health treatment)

Supporting information: Study protocol, Icf

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07694089
Lead sponsor
Akshitkumar MIstry
Collaborators
Cantex Pharmaceuticals Inc., James Graham Brown Cancer Center
Responsible party
Akshitkumar MIstry (Assistant Professor, University of Louisville) — Sponsor-investigator
First posted
Jul 9, 2026
Start date
Oct 1, 2026 (estimated)
Primary completion
Aug 1, 2029 (estimated)
Completion
Aug 1, 2029 (estimated)
Last update
Jul 9, 2026

Study contacts

Akshitkumar M Mistry, MD
Contact
a.mistry@uoflhealth.org
502-276-5030
UofL Health Brown Cancer Center
Contact
502-562-4370
Akshitkumar M Mistry, MD
principal investigator · UofL Health - Brown Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion